MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) today announced that Garry A. Neil, M.D., Chief Scientific Officer, Medgenics, Inc., has been appointed to the GTx, Inc. Board of Directors. Dr. Neil brings significant medical and drug development leadership to the GTx Board of Directors and a proven track record of turning new science into breakthrough commercial products. Dr. Neil will serve on both the Nominating & Governance and Scientific and Development Committees.
Spanning more than twenty years in the pharmaceutical industry, Dr. Neil held a number of senior positions within Johnson & Johnson, Astra Merck Inc., Astra Pharmaceuticals, AstraZeneca, and Merck KGaA. Dr. Neil is a fellow of the American College of Physicians and the American College of Gastroenterology, as well as a member of the American Association of Immunologists and the Society for Clinical Trials.
“We are extremely pleased to have Garry join our Board of Directors; under his leadership several important medicines for the treatment of cancer, anemia, infections, central nervous system and psychiatric disorders, pain, and genitourinary and gastrointestinal diseases gained initial or expanded approvals,” said Dr. Robert J. Wills, Executive Chairman of GTx. “Garry’s deep understanding of the needs of patients will also be invaluable to our team as we focus on developing novel targeted hormonal therapies to provide better medicines for patients.”
Since 2013, Dr. Neil has been the Chief Scientific Officer at Medgenics, Inc., a gene therapy company focused on treating patients with rare genetic and orphan diseases. Prior to Medgenics, he was a Partner and the Head of R&D at Apple Tree Partners, a life sciences private equity firm. From 2002 to 2012, Dr. Neil held various leadership positions including Corporate Vice President of Science & Technology at Johnson & Johnson, and Group President at Johnson & Johnson Pharmaceutical Research and Development. Prior to joining Johnson & Johnson, he held senior positions at Astra Merck, AstraZeneca, and EMD Pharmaceuticals.
Dr. Neil holds a B.S. from the University of Saskatchewan and an M.D. from the University of Saskatchewan College of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. He completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic. He held faculty positions at the Ludwig Institute for Cancer Research, the University of Iowa and the University of Pennsylvania (adjunct).
Dr. Neil serves on the Boards of Reagan-Udall Foundation and the Foundation for the U.S. National Institutes of Health (NIH), and is a past member of the Science Management Review Board of the NIH. He is past Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee, the PhRMA Foundation Board and he is the founding Chairman of TransCelerate BioPharma, Inc.
GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions.